⌘K
t
| Date | 14 Feb 2024 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 0975D |
LEI: 549300Q7EXQQH6KF7Z84
14 February 2024
RTW Biotech Opportunities Ltd
Monthly Valuation Update, January Factsheet
+2.5% NAV movement for the month
RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio") announces that the unaudited net asset value attributable to the ordinary shares of the Company (the "NAV") at the close of business on 31 January 2024 was US$407.1 million, or US$1.94 per ordinary share, +2.5% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
It is important to note that this NAV and January Factsheet do not reflect the completion of the Arix Bioscience plc ("Arix") transaction (the "Transaction"), which closed after January month-end with the new RTW Bio shares being admitted to trading on 13 February 2024. It does, however, include the previously announced acquisition of a 25.5% stake in Arix for a total consideration of US$57.1 million (representing £1.37 per Arix share) as reported on 22 January. On 31 January, the Arix stake amounted to 13.7% of NAV and was held in the "other public" segment of the portfolio, and as such it is not shown on the January Factsheet, which only shows core positions.
The Company intends to publish, at the soonest opportunity, an indicative and estimated pro forma NAV and NAV per share as at the closing date of the Transaction, reflecting the completion of the Transaction and new share issuance.
For Further Information:
|
RTW Investments, LP |
+44 20 7959 6361 |
|
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations |
|
|
|
|
|
Buchanan (PR & Communications Adviser) |
+44 20 7466 5107 |
|
Charles Ryland |
|
|
Henry Wilson |
|
|
George Beale |
|
|
|
|
|
Deutsche Numis (Joint Corporate Broker) |
+44 20 7260 1000 |
|
Freddie Barnfield |
|
|
Nathan Brown |
|
|
Euan Brown |
|
|
|
|
|
BofA Securities (Joint Corporate Broker) |
+44 20 7628 1000 |
|
Edward Peel |
|
|
Alex Penney
|
|
|
Cadarn Capital (Distribution & IR Partner) |
+44 73 6888 3211 |
|
David Harris |
|
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 (0) 14 8181 0100 |
|
Morgan Stanley Fund Services USA LLC |
+1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.